Apellis' Soliris rival gets a date at the FDA for a rare blood disorder, with potentially $400M worth of implications

Apellis $APLS is one step closer to catching its rival for the rare blood disorder PNH.

The Waltham, MA-based biotech announced that the FDA has begun priority review for its experimental medicine pegcetacoplan after the drug beat Alexion’s blockbuster Soliris in a head-to-head Phase III. Regulators have set a PDUFA date for May 14, 2021, and Apellis noted that no adcomm is currently expected.